20th INTERNATIONAL CONFERENCE ON ALZHEIMER’S DRUG DISCOVERY
September 16-17, 2019 • Jersey City, NJ (across from NYC on the Hudson)

PROGRAM

All sessions will be held at the Hyatt Regency Jersey City (Manhattan Ballroom, 9th Floor).

 

Sunday, September 15

5:00–7:00pm Registration

Monday, September 16

8:00am–5:30pmRegistration
8:00–9:00amContinental Breakfast
9:00–9:20Welcome & Introductory Notes
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation
9:20–9:50Biomarker-drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
Dimitrios Kapogiannis, MD—National Institutes of Health
9:50-10:00Discussion and Q&A
Session I: SMALL MOLECULE APPROACHES FOR ALZHEIMER’S DISEASE
Chair: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
10:00–10:05Session Overview: Lauren Friedman, PhD—Alzheimer’s Drug Discovery Foundation
10:05–10:25Pre-clinical Assessment of the Therapeutic Utility of Small Molecule Inhibitors of the Calcineurin/NFAT System in Alzheimer's Disease
Chris Norris, PhD—University of Kentucky
10:25–10:35Q&A
10:35–10:55 Exploratory Optimization of New CX3CR1 Modulators for the Treatment of AD
Grace (Beth) Stutzmann, PhD—Chicago Medical School/NeuroLucent, Inc
10:55–11:05Q&A
11:05–11:35EXHIBITOR SESSION BREAK
11:35–11:55Neuroprotective Small Molecule Inhibitors for the Treatment of Alzheimer's Disease
Brett Abrahams, PhD—Magnolia Neuroscience
11:55am–12:05pmQ&A
12:05–12:25EP2 Antagonists for the Suppression of Inflammation and Neuropathology in Alzheimer's Model
Thota Ganesh, PhD—Emory University
12:25–12:35Q&A
12:35–1:05POSTER SESSION
1:05–2:00
LUNCH
Session II: NOVEL APPROACHES FOR FRONTOTEMPORAL DEMENTIA
Chair: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
2:00–2:05Session Overview: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
2:05–2:25Detecting TDP-43 in CSF
Mari DeMarco, PhD—University of British Columbia
ADDF/Association for Frontotemporal Degeneration Partnership Program
2:25–2:35Q&A
2:35–2:55Novel Human FTLD Neuron and Microglia Cell Models for Drug Discovery
Steven Finkbeiner, MD, PhD—Gladstone Institutes/University of California, San Francisco
2:55–3:05Q&A
3:05–3:25Demonstration of Phase I Target Engagement in PSP
TBA
3:25–3:35Q&A
3:35–3:55Non-Invasive Brain Stimulation to Restore Cortical Plasticity in FTD
Alberto Benussi, MD—University of Brescia
ADDF/Association for Frontotemporal Degeneration Partnership Program
3:55–4:05Q&A
4:05–4:35EXHIBITOR SESSION BREAK
4:35–5:05 EMERGING CONCEPTS: DATA BLITZ
Chair: Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
Young Investigator #1:
Young Investigator #2:
Young Investigator #3:
5:05–5:15Closing Remarks and Announcement of Young Investigator Scholarships
Meriel Owen, PhD—Alzheimer’s Drug Discovery Foundation
5:15–7:00NETWORKING RECEPTION

Tuesday, September 17

7:30–9:00amContinental Breakfast
8:00–8:40SBIR Opportunities for Alzheimer’s Disease
Zane Martin, PhD——National Institute on Aging
8:50–9:20 KEYNOTE: The Use of Platform Trials in CNS Disorders
Sabrina Paganoni, MD—Massachusetts General Hospital/Harvard University
9:20-9:30Discussion and Q&A
Session III: CLINICAL TRIALS IN ALZHEIMER’S DISEASE
Chair: Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation
9:30–9:35 Session Overview: Alessio Travaglia, PhD—Alzheimer’s Drug Discovery Foundation
9:35–9:55Rasagiline Rescue in Alzheimer's Disease Clinical Trial
Jeff Cummings, MD—Cleveland Clinic
9:55–10:05Q&A
10:05–10:25CT1812 for the Treatment of Alzheimer’s Disease
Susan Catalano, PhD—Cognition Therapeutics
10:25–10:35Q&A
10:35–11:05EXHIBITOR SESSION BREAK
11:05–11:25Benfotiamine in Alzheimer's Disease, A Pilot Study
TBA
11:25–11:35Q&A
11:35–11:55Vascular Approaches for Alzheimer’s Treatment
Ihab Hijjar, MD—Emory Health Care
11:55am–12:05pmQ&A
12:05–12:35POSTER SESSION
12:35–1:15LUNCH
Session IV: NOVEL BIOMARKER APPROACHES
Chair: Nicole Bjorkland, PhD—Alzheimer’s Drug Discovery Foundation
1:15–1:20Session Overview: Nicole Bjorkland, PhD—Alzheimer’s Drug Discovery Foundation
1:20 –1:40Neuroimaging in Alzheimer’s Disease: ROI Based Approaches to FDG-PET for Clinical Trials
Dawn Matthews, PhD—ADMDx
1:40–1:50Q&A
1:50–2:10Resilience Biomarker NPTX2 and AD Progression
Paul Worley, PhD—Johns Hopkins University
2:10–2:20Q&A
2:20–2:40The Utility of cFLIP and MCL I and their Regulatory MicroRNAs as Novel Biomarkers of Alzheimer's Disease
Esmerina Tili, PhD—OSU/Gnome Diagnostics, LLC
2:40–2:50Q&A
2:50-3:10Ocular Approaches for Alzheimer’s Diagnosis
Swati More, PhD—University of Minnesota
3:10-3:20Q&A
3:20-3:30pmClosing Remarks
Howard Fillit, MD—Alzheimer’s Drug Discovery Foundation